Literature DB >> 12682561

Community-acquired pneumonia.

Julie Andrews1, Behzad Nadjm, Vanya Gant, Nandini Shetty.   

Abstract

Community-acquired pneumonia (CAP) remains an important cause of morbidity and mortality. Streptococcus pneumoniae is the most common pathogen and respiratory syncitial virus the most important viral pathogen in children. The role of urinary antigen testing and PCR for the diagnosis forS. pneumoniae infection has been an important adjunct to clinical examination, showing good sensitivity and specificity. Host-related immune responses play an important role in defining the severity of illness. Other than the use of Activated Protein C and immunization, the clinical use of therapies designed to modulate these abnormal responses remains largely experimental. The 7-valent vaccine represents a major advance in the prevention of invasive pneumococcal disease. The importance of effective triage and the deleterious effects of deviation from protocols are underscored. Continuous positive pressure ventilation and noninvasive mechanical ventilation are available as options for respiratory support in cases of severe CAP and require further evaluation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682561     DOI: 10.1097/00063198-200305000-00004

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  5 in total

Review 1.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

2.  Community-acquired pneumonia in elderly patients.

Authors:  John E Stupka; Eric M Mortensen; Antonio Anzueto; Marcos I Restrepo
Journal:  Aging health       Date:  2009

3.  Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study.

Authors:  Satoshi Inoue; Yuji Watanuki; Tetsuji Kaneko; Takashi Sato; Naoki Miyazawa; Takeshi Kaneko; Yoshiaki Ishigatsubo; Satoshi Morita; Yutaka Natsumeda; Shunsaku Mizushima
Journal:  BMJ Open       Date:  2011-07-18       Impact factor: 2.692

Review 4.  [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features].

Authors:  F Philippart
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

Review 5.  From virus to inflammation, how influenza promotes lung damage.

Authors:  Mitchell Klomp; Sumit Ghosh; Sohail Mohammed; M Nadeem Khan
Journal:  J Leukoc Biol       Date:  2020-09-08       Impact factor: 6.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.